Commerce Bank Buys Shares of 12,423 Mural Oncology plc (NASDAQ:MURA)

Commerce Bank bought a new stake in shares of Mural Oncology plc (NASDAQ:MURA) during the third quarter, HoldingsChannel reports. The institutional investor bought 12,423 shares of the company’s stock, valued at approximately $39,000.

A number of other large investors also recently added to or reduced their stakes in the business. Armistice Capital LLC acquired a new position in Mural Oncology during the 2nd quarter valued at about $5,300,000. Acadian Asset Management LLC acquired a new stake in shares of Mural Oncology in the 2nd quarter valued at approximately $998,000. Primecap Management Co. CA acquired a new stake in shares of Mural Oncology in the 2nd quarter valued at approximately $740,000. Renaissance Technologies LLC acquired a new stake in shares of Mural Oncology in the 2nd quarter valued at approximately $729,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Mural Oncology in the 2nd quarter valued at approximately $526,000. 80.21% of the stock is currently owned by institutional investors and hedge funds.

Mural Oncology Stock Performance

Shares of MURA stock opened at $4.04 on Thursday. The company has a market capitalization of $68.76 million and a P/E ratio of -0.43. The company’s 50 day moving average price is $3.44 and its two-hundred day moving average price is $3.36. Mural Oncology plc has a 52 week low of $2.88 and a 52 week high of $6.25.

Wall Street Analyst Weigh In

MURA has been the topic of a number of analyst reports. Raymond James initiated coverage on shares of Mural Oncology in a research report on Friday, October 4th. They issued a “strong-buy” rating and a $18.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Mural Oncology in a research report on Monday, November 11th.

Insiders Place Their Bets

In other Mural Oncology news, CFO Adam D. Cutler sold 7,421 shares of the firm’s stock in a transaction that occurred on Thursday, October 31st. The shares were sold at an average price of $3.41, for a total transaction of $25,305.61. Following the sale, the chief financial officer now directly owns 71,438 shares in the company, valued at approximately $243,603.58. This trade represents a 9.41 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.